Unaudited Results for the quarter ended 31.12.2025
TRANSPEK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transpek Industry's Board of Directors, at a meeting held on 4th February 2026, approved the unaudited financial results (both standalone and consolidated) for Q3 FY26 and the nine months ended 31st December 2025. The results were first reviewed by the Audit Committee earlier the same day. The statutory auditors, Bansi S. Mehta & Co., issued a clean Limited Review Report on both the standalone and consolidated results, stating that nothing came to their attention suggesting the results were not prepared in accordance with applicable accounting standards. The consolidated results include the wholly owned subsidiary Transpek Creative Chemistry Private Limited. The insider trading window, which had been closed, re-opens from 7th February 2026. Specific revenue, profit, or margin numbers were not included in the filing text provided.
This is a routine quarterly compliance filing with a clean (unqualified) auditor's review report, signalling no immediate red flags. The actual financial numbers in the attached results will be the key driver of stock reaction, but the absence of any auditor qualifications is mildly reassuring for shareholders.